Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure

American Journal of Health-System Pharmacy

Volumn 68, Issue 4, 2011, Pages 328-333

  Cyr, Philip L ^a   Slawsky, Katherine A ^a   Olchanski, Natalia ^a   Krasa, Holly B ^b   Gos, Thomas F ^c   Zimmer, Christopher ^b   Hauptman, Paul J ^d,e  

^a Boston Healthcare Associates Inc   (United States)

^b Otsuka Pharmaceutical Development and Commercialization   (United States)

^c Boston Healthcare Associates   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

Author keywords

Heart failure; Hospitals; Hyponatremia; Tolvaptan; Vasopressin antagonists

Indexed keywords

SODIUM; TOLVAPTAN;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH CARE QUALITY; HEART FAILURE; HUMAN; HYPONATREMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; TREATMENT OUTCOME;

EID: 79953290293     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100217     Document Type: Article

References (23)

1. Schrier RW. The patient with hyponatremia or hypernatremia. In: Schrier RW, ed. Manual of nephrology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2000:21-36.
2. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am. 2003; 32:459-81. (Pubitemid 36666228)
3. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc. 2006; 4:1-11.
4. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006; 119(suppl 1):S30-5.
5. Zilberberg MD, Exuzides A, Spalding J et al. Epidemiology, clinical, and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008; 24:1601-8. (Pubitemid 351929058)
6. Klein L, O'Connor CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005; 111:2454-60. (Pubitemid 40696133)
7. Gheorghiade M, Gattis WA, O'Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004; 291:1963-71. (Pubitemid 38544277)
8. Gheorghiade M, Abraham WT, Albert NM et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28:980-8. (Pubitemid 47343897)
9. Gheorghiade M, Rossi JS, Cotts W et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med. 2007; 167:1998-2005. (Pubitemid 47606641)
10. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by convertingenzyme inhibition in patients with severe chronic heart failure. Circulation. 1986; 73:257-67. (Pubitemid 16127402)
11. Lee DS, Austin PC, Rouleau JL et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003; 290:2581-7. (Pubitemid 37443288)
12. Verbalis JG, Goldsmith SR, Greenberg A et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007; 120(suppl):S1-21.
13. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005; 46:1785-91. (Pubitemid 41579797)
14. Konstam MA, Gheorghiade M, Burnett JC et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007; 297:1319-31. (Pubitemid 46513233)
15. Gheorghiade M, Konstam MA, Burnett JC et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007; 297:1332-43. (Pubitemid 46513234)
16. Hauptman PJ, Swindle J, Burroughs TE et al. Resource utilization in patients hospitalized with heart failure: insights from a contemporary national hospital database. Am Heart J. 2008; 155:978-85.
17. Gheorghiade M, Orlandi C, Burnett JC et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005; 11:260-9. (Pubitemid 40626781)
18. Blair J, Zannad F, Konstam MA et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure: results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008; 52:1640-8.
19. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000.
20. Wong LL, Verbalis JG. Systemic diseases associated with disorders of water homeostasis. Endocrinol Metab Clin North Am. 2002; 31:121-40. (Pubitemid 34578617)
21. Shea AM, Hammill BG, Curtis LH et al. Medical costs of abnormal serum sodium levels. J Am Soc Nephrol. 2008; 19:764-70.
22. Lee WC, Chavez YE, Baker T et al. Economic burden of heart failure: a summary of recent literature. Heart Lung. 2004; 33:362-71.
23. Rossi J, Bayram M, Udelson JE et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care. 2007; 9:82-6. (Pubitemid 46955230)